Please login to the form below
PARP inihibitor
This page shows the latest PARP inihibitor news and features for those working in and with pharma, biotech and healthcare.
Pfizer’s Talzenna cleared for breast cancer in Europe
Fourth to market aims to carve out niche. EU regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with BRCA-mutated breast cancer, opening up another front in a ... Meanwhile, Pfizer’s drug will also have to compete with two
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Novavax gets $1.6bn from US government for coronavirus vaccine
- Communiqué Awards 2020: Results - Communiqué Awards
- FDA approves Roche’s Actemra COVID-19 trial
- Communiqué Awards 2020: Results - Communiqué Awards
- Mesoblast expands compassionate use COVID-19 programme
- Regeneron’s COVID-19 antibody cocktail enters phase 3 trial
- Intelligence that redefines success
- IFPMA launches AMR Action Fund to tackle antimicrobial resistance
- Merck expands partnership with Zymeworks for multispecific antibodies
- Novartis reveals full phase 3 results for Enerzair Breezhaler
- Artificial Intelligence in Digital Therapeutics
- CHECKLIST 04: Let’s make your patient recruitment strategies a success
PMHub
Porterhouse Medical Group
The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...
Latest intelligence
- CHECKLIST 04: Let’s make your patient recruitment strategies a success
- From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
- Multichannel engagement and the need for greater understanding of European markets
- By Laurence Olding and Georgina James...
- A snapshot of… Exscientia
- ...
Quick links
Infographics
